Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of p53 synthetic long peptide vaccine plus interferon-alfa in treated colorectal cancer
NL-OMON33981Phase 1Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics, Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of p53 synthetic long peptide vaccine and peginterferon alfa-2b in colorectal cancer (CRC), sponsored by Leiden University Medical Center. Primary endpoints: Safety, Directly ex-vivo detectable p53-specific CD4+ T-cell response and 4 more. Started Sep 2009; status: recruiting.
02
Drugs
p53 synthetic long peptide vaccinepeginterferon alfa-2b
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON33981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33981.